Samsara Biocapital, LP

Director Srinivas Akkaraju buys 244,300 KLRS shares at $4.83 ($1.2M); stock down 58.6% from 52-week high, -22.3% in 30 days.

Srinivas Akkaraju, a Director at unprofitable Kalaris Therapeutics (full-year net income: $-10,856,000.00), purchased 244,300 shares at $4.83 on 2026-05-20, bringing his holding to 19,408 shares post-transaction. The purchase represents a notable dollar commitment ($1,179,969.00) into a stock trading at $4.92 currently, down 58.6% from its 52-week high of $11.88 and off 50.8% over the past 90 days. His cross-ticker track record shows strong timing (20 prior buys averaging +197.1% 90-day returns with a 95.00% win rate), yet his single prior buy at KLRS (2025-12-18) produced a -27.7% 90-day return, indicating this ticker has not aligned with his typical execution pattern. The company's unprofitable status and continued downward price momentum provide limited fundamental support for the accumulation.

Director Akkaraju Srinivas bought 479,847 shares of KLRS at $10.42 ($5.0M), raising holdings by 32.0% as stock trades 28.0% below 52-week high.

Akkaraju Srinivas, a Director, deployed $5,000,005.74 to purchase 479,847 shares at $10.42, increasing his stake from 1,500,000 shares to 1,979,847 shares. This represents a 32.0% increase in his holdings. The purchase was made when the stock trades at $8.26, which is 28.0% below its 52-week high of $11.47 and 15.2% down over the past 30 days, suggesting the insider acquired shares following recent weakness. Notably, Srinivas's cross-ticker track record shows 20 prior open-market buys with an average 90-day return of +129.8% and a 100.00% win rate, though the company itself is unprofitable with net income of $-11,894,000.00 over its most recent full fiscal year. The large dollar commitment and aggressive holding expansion by an insider with a strong historical track record at capital deployment warrant investor attention, particularly given the depressed relative price at which the purchase occurred.

Samsara BioCapital GP, LLC bought 600,000 shares of MLYS at $13.50 on 2025-03-13, increasing holdings to 5,674,916 shares (+11.8%); cluster buy pattern with 3 other insiders in 14 days.

Samsara BioCapital GP, LLC, a 10% owner, purchased 600,000 shares at $13.50, adding $8,100,000.00 in capital and raising its stake by 11.8% to 5,674,916 shares. The purchase occurred as the stock traded 5.0% below its 52-week high of $14.96 and has gained 38.9% in the preceding 30 days and 15.1% over 90 days. The same insider's prior MLYS purchase on 2024-02-12 achieved a 90-day return of 0.2%, indicating mixed prior execution at this ticker. Notably, 3 other insiders also bought within the past 14 days, forming a cluster buy pattern. However, the company remains unprofitable with a net income of $-56,342,000.00, which constrains confidence in fundamental support for the buying activity.

10% owner Samsara BioCapital bought 48,770 shares (48.8K) totaling $1,259,622.58 ($1.3M) at blended avg $25.83; part of cluster buy pattern

Samsara BioCapital GP, LLC executed 4 separate purchases totaling 48,770 shares for $1,259,622.58 on 2024-11-26, increasing its holding to 1,717,127 shares post-transaction. The filing coincides with a cluster buy pattern: 2 other insiders also purchased within the past 14 days. Stock has declined -63.9% from its 52-week high of $71.53 and -43.8% over the past 30 days, trading near the blended purchase price of $25.83. The company remains unprofitable (net income $-20,217,000.00 for latest quarter; negative net income for full fiscal year) with zero latest-quarter revenue, elevating execution risk. Samsara's cross-ticker track record shows 75.00% win rate and +46.7% average 90-day return on prior buys, but this metric spans multiple tickers and does not indicate same-ticker conviction or timing accuracy at Neurogene.